Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone

Citation for published version:

Digital Object Identifier (DOI):
10.1136/jmg.2004.023895

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Medical Genetics

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Association of oestrogen receptor α gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone

O M E Albagha, U Pettersson, A Stewart, F E A McGuigan, H M MacDonald, D M Reid, S H Ralston


See end of article for authors’ affiliations

Correspondence to: Dr Stuart H Ralston, The Bone Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK; s.ralston@abdn.ac.uk

Revised version received 9 September 2004
Accepted for publication 12 September 2004

Background: The gene encoding oestrogen receptor α (ESR1) appears to regulate bone mineral density (BMD) and other determinants of osteoporotic fracture risk.

Objective: To investigate the relation between common polymorphisms and haplotypes of the ESR1 gene and osteoporosis related phenotypes in a population based cohort of 3054 Scottish women.

Results: There was a significant association between a common haplotype “px”, defined by the PvuII and XbaI restriction fragment length polymorphisms within intron 1 of the ESR1 gene, and femoral neck bone loss in postmenopausal women who had not received hormone replacement therapy (n = 945; p = 0.009). Annual rates of femoral neck bone loss were ~14% higher in subjects who carried one copy of px and 22% higher in those who carried two copies, compared with those who did not carry the px haplotype. The px haplotype was associated with lower femoral neck BMD in the postmenopausal women (p = 0.02), and with reduced calcaneal broadband ultrasound attenuation (BUA) values in the whole study population (p = 0.005). There was no association between a TA repeat polymorphism in the ESR1 promoter and any phenotype studied, though on long range haplotype analysis subjects with a smaller number of TA repeats who also carried the px haplotype had reduced BUA values.

Conclusions: The ESR1 px haplotype is associated with reduced hip BMD values and increased rates of femoral neck bone loss in postmenopausal women. An association with BUA may explain the fact that ESR1 intron 1 alleles predict osteoporotic fractures by a mechanism partly independent of differences in BMD.

METHODS

Study subjects

The study group comprised white women who were randomly selected from the community health index, a database of all patients registered with a general practitioner from a 25 mile radius of Aberdeen, a city in the north east of Scotland, as part of a large prospective population based screening programme for osteoporotic fracture risk (the APOSS study).20 The screening programme involved approximately 7000 women who were invited by letter to undergo

Abbreviations: APOSS, Aberdeen prospective osteoporosis screening study; BMD, bone mineral density; BMI, body mass index; BUA, broadband ultrasound attenuation; HRT, hormone replacement therapy; LRH, long range haplotype; QUS, quantitative ultrasound; SNP, single nucleotide polymorphism
bone mineral density (BMD) measurements between 1990 and 1994. In all, 5,119 women (~73%) attended for evaluation and underwent BMD measurement at the lumbar spine and femoral neck and completed a risk factor questionnaire. This included details of fracture history, menopausal status, and use of hormone replacement therapy (HRT). Participants were weighed on a set of balance scales calibrated to 0.05 kg (Seca, Hamburg, Germany) and height was measured using a stadiometer (Holtain, Crymych, Dyfed, UK). All women were invited to undergo further assessment between 1997 and 1999, and 3,882 women (75.8%) re-attended for evaluation. Baseline investigations were repeated at the follow up visit and information was gathered on fracture history by completion of a questionnaire. Calcaneal broadband ultrasound attenuation and speed of sound was measured and blood samples were obtained for DNA extraction from 3,054 women who consented. Women were classified as premenopausal if they were menstruating regularly, as perimenopausal if menstruation was irregular and/or up to six months had elapsed since their last period, and postmenopausal if menstruation had ceased for six months or more. Information gathered on menopausal status and HRT use identified five categories as follows: 1, premenopausal; 2, perimenopausal; 3, postmenopausal, no HRT; 4, postmenopausal, previous HRT user; 5, postmenopausal, current HRT user.

Fracture assessment at the baseline visit (prevalent fractures) was based on the questionnaire, whereas fracture data obtained at the follow up visit (incident fractures occurring between baseline and follow up) were confirmed by scrutiny of hospital records and x-ray reports. Owing to the young age of the study subjects, the number of incident fractures observed in this population was small (nine hip fractures and 15 clinical vertebral fractures). Because of this, we did not analyse the relation between ESRI gene polymorphisms and bone mass.

Quantitative ultrasound measurements
Quantitative ultrasound (QUS) measurements were carried out using a Hologic Sahara scanner (Hologic Inc, Bedford, Massachusetts, USA). This measures speed of sound (SOS, m/s) and broadband ultrasound attenuation (BUA, dB/MHz), by assessing the “loss” of sound waves as they travel across the calcaneus. This is a dry system where transducers are in direct contact with the skin, and an oil based gel is used as a coupling device. In vitro precision (coefficient of variation) in our hands is less than 1% when examining 10 phantoms.

Genotyping
Genomic DNA was extracted from peripheral blood leucocytes using the Nucleon II DNA extraction kit (Scotlab, Coatbridge, Lanarkshire, UK) according to the manufacturer’s instructions. The PvuII and XbaI polymorphisms are 45 bp apart and located approximately 400 bp upstream of exon 2. Genotypes for the PvuII and XbaI polymorphisms...
were determined by direct DNA sequencing. A 346 bp polymerase chain reaction (PCR) product containing both polymorphic sites was amplified by PCR as described previously. PCR products were then cleaned using ExoSAP IT™ (USB Corp, Cleveland, Ohio, USA) and sequenced using the DYEnamic ET dye terminator cycle sequencing kit (Amersham Pharmacia Biotech, Uppsala, Sweden) and the T7 polymerase (Qiagen). The PCR product was amplified in 20 μl using 1x PCR buffer (Qiagen, Crawley, West Sussex, UK), 2 μl of 5 molar of oligonucleotide primer mix (5′-GAACAGCAATCTCACCGACTACAC-3′), and reverse primer (5′-GCAGAATCAAATATCCAGATG-3′), with upper case letters signifying the absence of, and lower case letters the presence of, the restriction site.

The following thermal cycling conditions were used on a Gene Engine thermocycler (MJ Research Inc, Watertown, Massachusetts, USA): one cycle of 94°C for four minutes, 58°C for 30 seconds, 72°C for 30 seconds) followed by 30 cycles of (94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds). The length of PCR product was determined by analysis on a MEGABACE-1000 automated DNA sequencer (Amersham Pharmacia Biotech). The genotypes were represented as PvuII (PvuII) and XbaI (XbaI), with upper case letters signifying the absence of, and lower case letters the presence of, the restriction site.

The TA repeat polymorphism of the ESR1 gene was investigated by PCR using a FAM labelled forward primer (5′-FAM-GACGACGATATCTACACC-3′) and reverse primer (5′-GCAGAACATCTCACCGACTACAC-3′) in a 25 μl PCR reaction containing: 2.5 μl 10X PCR buffer (Qiagen, Crawley, West Sussex, UK), 0.2 μl of dNTP (10 mM each), 5.0 μl of Q solution, 2.5 μl of oligonucleotide primer mix (5 μM each of forward and reverse primer), 0.125 μl of 5 U/μl Taq DNA polymerase (Qiagen), and 50–100 ng genomic DNA. The reaction volume was made up to 25 μl using deionised water. The following thermal cycling conditions were used on a Gene Engine thermocycler (MJ Research Inc, Watertown, Massachusetts, USA): one cycle of (94°C for four minutes, 58°C for 30 seconds, 72°C for 30 seconds) followed by 30 cycles of (94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds). The length of PCR product was determined by analysis on a MEGABACE-1000 using the Genetic Profiler™ software (Amersham Pharmacia Biotech). Genotypes were scored independently by two different individuals. To check for genotyping errors, 50 DNA samples were selected randomly and reanalysed. All genotypes were identical to those obtained from the first round analysis. The genotyping success rate was 94% for PvuII and XbaI and 96% for TA repeat polymorphism. Our genotyping method for TA repeat was found to estimate systematically one less TA repeat than the method used by researchers who also studied this polymorphism in a cohort of individuals from the Rotterdam study. This was found by independent genotyping of 50 samples from our population carried out by the Rotterdam research group.

### Statistical analysis

Haplotypes were inferred from genotype data using the PHASE software program. The probability of the PvuII-XbaI haplotype phase being correctly inferred was 0.99, and the average probability for the TA-PvuII-XbaI haplotype being correctly inferred was 0.987 (95% confidence interval, 0.983 to 0.991). Statistical analyses were carried out using SPSS version 10.0 (SPSS Inc, Chicago, Illinois, USA). Differences in BMD, BUA, and bone loss between the genotype and haplotype groups were tested using analysis of covariance (ANCOVA) to adjust for confounding factors such as age, body mass index (BMI), menopausal status, and hormone replacement therapy (HRT) use. For the haplotype analysis, study subjects were coded according to whether they had two copies, one copy, or no copies of the haplotype under investigation. Multiple linear regression analysis was used to test for gene dose effects. Power calculations indicated that the study had >97% power to detect differences in BMD and BUA of 0.1 SD units between genotypes assuming a minor allele frequency of 30%. Probability (p) values of <0.05 were considered significant. We also used a modified Bonferroni correction to adjust for the number of independent tests carried out, taking into account that the three polymorphisms are in strong linkage disequilibrium and the variables tested are strongly correlated with each other. The corrected threshold of significance was p<0.015. As it has been argued that the Bonferroni correction may be too conservative, we present the unadjusted p values in the text.

### RESULTS

#### Characteristics of study population

Table 1 shows relevant demographic characteristics of the study population at the baseline and follow up visits. The average age of the study subjects was 48.5 years at baseline, and at this time 46.3% of women were postmenopausal. The average age at the follow up visit was 54.7 years and the

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ESR1 polymorphism</th>
<th>ESR1 haplotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline LS BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.44</td>
<td>0.91</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.47</td>
<td>0.97</td>
</tr>
<tr>
<td>Baseline FN BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.90</td>
<td>0.79</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.92</td>
<td>0.73</td>
</tr>
<tr>
<td>Changes in LS BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.82</td>
<td>0.77</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.96</td>
<td>0.77</td>
</tr>
<tr>
<td>Changes in FN BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.37</td>
<td>0.69</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.34</td>
<td>0.48</td>
</tr>
<tr>
<td>Calcaneal BUA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.37</td>
<td>0.06</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.42</td>
<td>0.09</td>
</tr>
<tr>
<td>Calcaneal SOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.45</td>
<td>0.09</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.57</td>
<td>0.14</td>
</tr>
</tbody>
</table>

Values presented are p values obtained from analysis of variance for crude data and analysis of covariance for the adjusted data. Lumbar spine and femoral neck bone mineral density (BMD) values were adjusted for age, body mass index (BMI), menopausal status, and hormone replacement therapy (HRT) use. Change in BMD values are presented as per cent per year and were adjusted for age, BMI, change in BMI, baseline BMD, menopausal status, and HRT use. Broadband ultrasound attenuation (BUA) and speed of sound (SOS) values were adjusted for age, BMI, BMD, menopausal status, and HRT use. FN, femoral neck; LS, lumbar spine.
majority of women were postmenopausal (89.9%). Values for age, BMI, lumbar spine BMD, and femoral neck BMD at the baseline visit were, as expected, significantly different from those at the follow up visit (p<0.001). The average bone loss per year over the 6.2 years follow up was 0.61% and 0.74% at lumbar spine and femoral neck, respectively. Table 1 also shows BMD and QUS values in the study population according to menopausal status and HRT use. At the follow up visit, 59% of the women were either current or previous HRT users. There was a significant association between HRT use and age at menopause, so that subjects who were current HRT users had earlier age at menopause (mean (SD), 44.6 (8.6) year) than those with previous HRT treatment (46.5 (6.6) years) or those without HRT treatment (48.4 (5.7) years) (p<0.001).

Genotype and haplotype frequencies
On DNA sequencing analysis, we were only able to detect the PvuII and XbaI polymorphisms in our population, even though single nucleotide polymorphisms (SNP) databases suggest the presence of four additional SNPs in the sequenced region. We conclude therefore that these SNPs are absent or very rare in our population. The genotype frequencies for the PvuII and XbaI polymorphisms were: PP = 643 (22.4%), Pp = 1383 (48.2%), pp = 845 (29.4%), Xx = 347 (12.1%), Xx = 1328 (46.3%), and xx = 1193 (41.6%). These were in Hardy–Weinberg equilibrium and are similar to those previously reported in white populations.29–31 The PvuII-XbaI haplotype frequencies were: PX = 1960 (34.5%),Px = 685 (12.0%),pX = 47 (0.8%), and px = 2998 (52.7%). There was strong linkage disequilibrium between PvuII and XbaI polymorphisms (D'D = 0.956, p<0.000001) and two common haplotypes (PX and px) accounted for 87.1% of alleles defined by these two polymorphisms, as previously reported in white populations.30–31 For the TA repeat polymorphism, we observed 23 different alleles with TA repeat number ranging between 8 and 30 (supplementary figure; see on the JMG website at www.jmedgenet.com/supplemental). This polymorphism showed a bimodal distribution, with two peaks at 15 repeats (31.6% of alleles) and 24 repeats (10.2% of alleles), and a breakpoint at 18 TA repeats as reported previously.29–31 For statistical analysis, TA repeat alleles were classified into two groups on the basis of whether the number of repeats was above the breakpoint (“H alleles”): >18 repeats or below (“L alleles”: ≤18 repeats). When divided upon this basis, the TA repeat genotype frequencies were LL = 867 (29.5%); LH = 1433 (48.7%); and HH = 643 (21.8%). Strong linkage disequilibrium was observed between TA repeat and PvuII-XbaI polymorphisms, such that low numbers of TA repeats (L) were in strong linkage disequilibrium with the “p” allele of the PvuII polymorphism (D' = 0.755; p<0.000001) and the “x” allele of the XbaI polymorphism (D' = 0.803; p<0.000000). Long range haplotypes (LRH) defined by the TA, PvuII, and XbaI polymorphisms are shown in table 2. All eight possible haplotypes were found, and two common ones—“L-p-x” (47.17%) and “H-p-x” (30.96%)—accounted for 78.13% of the alleles observed, in keeping with those reported previously in elderly Dutch subjects.32

Association between ESR1 alleles and osteoporosis related phenotypes
We found no significant association between any of the ESR1 polymorphisms or haplotypes and BMD at the lumbar spine or femoral neck at baseline in the whole study population, or with annual rates of bone loss (table 3). Similarly, we found no association between ESR1 alleles and other confounding variables such as age, BMI, or age at menopause (data not shown). Analysis of PvuII-XbaI haplotypes in relation to calcaneal QUS at follow up showed that BUA values were significantly reduced in subjects carrying the px haplotype (mean (SEM) BUA, 75.0 (0.4); n = 1743) compared with those without this haplotype (77.1 (0.7); n = 532) (p = 0.005). The results remained significant after adjusting BUA values for age, BMI, BMD, menopausal status, and HRT use (px BUA = 75.0 (0.4); no px BUA = 77.2 (0.7)) (p = 0.006). A similar trend was observed for calcaneal speed of sound (SOS) but the results were of borderline significance (table 3). There was no significant association between the TA repeat polymorphism and BUA except when the data were analysed as long range haplotype with the intron 1 polymorphisms, when we observed reduced BUA and SOS values in carriers of the L-p-x haplotype (BUA = 74.8 (0.4); SOS = 1551.9 (0.8); n = 1570) compared with subjects who did not carry this haplotype (BUA = 77.2 (0.7); SOS = 1555.6 (1.3); n = 618) (p = 0.003 and 0.018, respectively). This result remained statistically significant after adjusting for age, BMI, BMD, menopausal status, and HRT use (L-p-x BUA = 74.9 (0.4), no L-p-x BUA = 77.0 (0.6); L-p-x SOS = 1552.2 (0.8), no L-p-x SOS = 1555.4 (1.2)) (p = 0.005 and 0.019, respectively).

Table 4 Association between ESR1 alleles, follow up bone mineral density, and bone loss in postmenopausal women who were not taking hormone replacement therapy

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number of copies of px haplotype</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Number of cases</td>
<td>212</td>
<td>433</td>
</tr>
<tr>
<td>LS BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.995 (0.012)</td>
<td>0.998 (0.008)</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.996 (0.011)</td>
<td>0.997 (0.007)</td>
</tr>
<tr>
<td>FN BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>0.842 (0.009)</td>
<td>0.833 (0.006)</td>
</tr>
<tr>
<td>Adjusted</td>
<td>0.842 (0.008)</td>
<td>0.833 (0.005)</td>
</tr>
<tr>
<td>LS BMD change</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>−1.273 (0.072)</td>
<td>−1.348 (0.052)</td>
</tr>
<tr>
<td>Adjusted</td>
<td>−1.273 (0.068)</td>
<td>−1.356 (0.048)</td>
</tr>
<tr>
<td>FN BMD change</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude</td>
<td>−1.063 (0.069)</td>
<td>−1.231 (0.052)</td>
</tr>
<tr>
<td>Adjusted</td>
<td>−1.051 (0.065)</td>
<td>−1.204 (0.046)</td>
</tr>
</tbody>
</table>

Values are mean (SEM). Lumbar spine and femoral neck bone mineral density (BMD) values were adjusted for age, body mass index (BMI), and years since menopause; change in BMD values (per cent per year) were adjusted for age, BMI, change in BMI, baseline BMD, and years since menopause. FN, femoral neck; LS, lumbar spine.
In view of the fact that HRT is known to have a profound influence on bone loss, we investigated annual rates of bone loss in the subgroup of women who were or had become postmenopausal at the second visit and who had not taken HRT (table 1). As expected, these women lost more bone than premenopausal women and HRT users. No difference was observed in distribution of ESR1 polymorphisms or haplotypes in these three groups (data not shown). A significant association was found between the px haplotype and bone loss at the femoral neck in postmenopausal women not taking HRT, however, and this remained significant after adjustment for age, BMI, changes in BMI, baseline BMD, and years since menopause (table 4).

There was clear evidence of a gene dose effect, such that the annual percentage fall in femoral neck BMD increased by 11.8% per copy of the px haplotype (p = 0.009). When the analysis was repeated using information from the TA repeat polymorphism, the same trends were observed for the L·p·x haplotype but the result was not significant (p = 0.06).

Analysis of BUA in the non-HRT users showed that subjects with two copies or one copy of the px haplotype had lower BUA values (73.1 (0.7); n = 518) than those without this haplotype (73.8 (1.3); n = 166), but this difference was not significant (p = 0.60), possibly because the number of individuals with BUA data in the non-HRT user group was small (684) compared to the total study population (2275). In keeping with this, we estimated that a subgroup size of more than 1250 would be required to attain 90% power to detect the difference in BUA observed between the genotype groups in the whole study population (0.14 SD units).

Of the 366 subjects in the non-HRT users, 321 also provided calcaneal ultrasound data. As expected, these women lost more bone than postmenopausal at the second visit and who had not taken HRT. The annual rates of femoral neck bone loss were about 14% higher in subjects who carried one copy of px and 22% higher in those carrying two copies compared with individuals who did not carry the px haplotype. Reflecting this, we also detected an association between the px haplotype and femoral neck BMD values were 1% lower in px heterozygotes and 3% lower in px homozygotes at follow up than in subjects who did not carry the px allele.

We also found a strong association between the px allele and broadband ultrasound attenuation at the calcaneus. This was observed in the whole study population and HRT users, and the association remained significant after adjusting for BMD and confounding factors such as age, BMI, and menopausal status. While the association we observed between calcaneal SOS and ESR1 polymorphisms was much weaker, previous studies in a large white cohort have shown that BUA is a better predictor of fracture risk than SOS. The association between BUA and the px allele in non-HRT users did not reach statistical significance although this could have reflected the small sample size of this subgroup.

There have been few previous studies of ESR1 polymorphisms in relation to quantitative ultrasound properties of bone. Those that have been done showed an association between the ESR1 XbaI polymorphism and calcaneal quantitative ultrasound (QUS) indices in young white women aged 18 to 35 years and in Korean postmenopausal women. While neither of these groups carried out haplotype analysis, both studies reported reduced QUS values (stiffness index and BUA) in association with the x allele, which is in broad agreement with the findings reported here, where the px haplotype was associated with reduced BUA. In another study, no association was observed between the XbaI polymorphism and calcaneal QUS in postmenopausal women taking HRT, although the sample size in that study was about one fifth as large as the population described here. The present study is the first to investigate haplotypes of all three ESR1 polymorphisms in relation to BUA and the first to report an association with calcaneal BUA independent of BMD. The association we observed with BUA is of relevance in light of a recent meta-analysis which showed that carriers of the XX genotype had a substantially reduced risk of osteoporotic fractures (odds ratio 0.66) when compared with

DISCUSSION

The ESR1 gene encoding the oestrogen receptor α is a strong candidate for the genetic regulation of bone mass, bone remodelling, and postmenopausal bone loss. However, studies of ESR1 alleles in relation to BMD have yielded inconsistent results, possibly because most studies have been of small sample size and involved subjects of different ages, menopausal status, and ethnic background. In this study, we investigated the relation between ESR1 polymorphisms and several phenotypes relevant to the pathogenesis of osteoporotic fractures in a large population based cohort study of white women from Scotland who had been prospectively followed for an average of 6.2 years. While we observed no association between ESR1 alleles and BMD or bone loss in the whole study population, there was a significant association between the px haplotype and rates of bone loss at the femoral neck in postmenopausal women who had not taken HRT. The annual rates of femoral neck bone loss were about 14% higher in subjects who carried one copy of px and 22% higher in those carrying two copies compared with individuals who did not carry the px haplotype.

Figure 1 Evolutionarily conserved regions in the human ESR1 gene compared with the mouse (upper panel) and rat (lower panel) genome. E1 and E2, exons 1 and 2. The first intron spans approximately 34 kb and is shown as a black box (http://ecrbrowser.dcode.org/).
xx homozgyotes, and that this was out of proportion to the relatively small association between the Xbal polymorphism and BMD (approximately 0.15 g/cm²). This raises the possibility that ESR1 polymorphisms might influence fracture risk by an effect on bone quality that is captured by BUA measurements but not by BMD measurements.6

In a previous study of older postmenopausal women derived from the same region of the United Kingdom (mean age, 64.4 years), we observed an association between the Px haplotype and BMD. These results were based on a small sample size (n = 206), however, and emphasise the importance of carrying out large scale studies for the genetic dissection of complex traits such as BMD.11 The association we observed in the present study between the px haplotype and increased rates of postmenopausal bone loss is in broad agreement with the findings previously reported in a cohort of elderly women from the Rotterdam study, where the px haplotype was associated with reduced lumbar spine BMD and an increased risk of vertebral fracture.12 While these investigators did not investigate allelic associations with bone loss, our data would be consistent with the hypothesis that ESR1 alleles regulate BMD by affecting bone loss rather than peak bone mass. The fact that the association we observed was restricted to a group of postmenopausal women who had not taken HRT is expected, given the known protective influence of HRT on rates of bone loss. In view of this, we speculate that under conditions of oestrogen sufficiency, such as in premenopausal women and HRT users—the association between ESR1 polymorphisms and bone turnover may be masked but may become progressively more apparent with increasing age in postmenopausal women who are oestrogen deficient.

The association we observed between ESR1 polymorphisms and bone loss was stronger for femoral neck than for lumbar spine. Although lumbar spine would be expected to be the more sensitive site to changes in HRT, the associated site may vary between different populations. Previous meta-analysis of ESR1 polymorphisms showed differences in the skeletal site associated with ESR1 polymorphisms among the different populations, and when all populations were analysed together the study showed equal effect of ESR1 alleles on lumbar spine and femoral neck BMD.13

There has previously been controversy over whether the associations between BMD and polymorphisms in the 5′ region of the ESR1 gene are driven by the intron 1 polymorphisms or the TA repeat polymorphism in the ESR1 promoter. Some investigators have reported that the TA repeat polymorphism is primarily responsible for driving the association with BMD,5,10 whereas others, including our own group, have reported that the association is driven by the intron 1 alleles.5,11 In the present study we found no significant association between the ESR1 TA repeat polymorphisms and bone related phenotypes except on long range haplotype analysis, where subjects with a low number of TA repeats who had carried the px haplotype were found to have reduced BUA values. Although this suggests that in our population the association we observed was primarily driven by the px haplotype, it is difficult to be confident about this, given the strong linkage disequilibrium that exists between these polymorphisms.

While ESR1 is one of the most intensively studied candidate genes for osteoporosis susceptibility, the mechanisms that underlie the associations between bone phenotypes remain unclear. Previous studies have shown that the PvuII polymorphism lies within consensus recognition sites for the AP4 and Myb transcription factors.5,11,12 Studies using promoter-reporter assays have shown that the PvuII polymorphism influences Myb driven transcription in vitro,12 and other studies have shown that both Xbal and PvuII polymorphisms also influence reporter gene transcription in vitro.13 In this regard, it is of interest that the PvuII and Xbal polymorphisms are located within a region that is 70–80% conserved in the human, mouse, and rat genomes, whereas the TA repeat polymorphism is not conserved to any significant extent across species (fig 1). While our observations would be consistent with a direct functional effect of the PvuII and Xbal polymorphisms on ESR1 gene transcription we cannot exclude the possibility that these polymorphisms are in linkage disequilibrium with causal polymorphisms elsewhere in the ESR1 gene. Further functional analysis will be required to investigate this possibility.

ACKNOWLEDGEMENTS

We are grateful to S Main, A Bassitt, S Bear and G Taylor for their technical assistance. We also thank Dr A Uitterlinden and colleagues (Erasmus Medical Centre, Rotterdam, Netherlands) for assistance in validating the TA repeat genotyping methods.

This work was partially supported by project grants from the Arthritis Research Campaign (R0544), chief Scientist office of the Scottish Executive (CZB/4/18), the Medical Research Council (G9823281), and the European Commission (GENOMOS project QLRT-2001-02629). AS is an Arthritis Research Campaign postdoctoral research fellow (S0693), OMEA holds an Arthritis Research Campaign lecturer award (R0992).

Supplementary figure. The ESR1 TA repeats polymorphism allele distribution in the study population. The figure can be viewed on the JMG website: www.jmedgenet.com/supplemental

Authors' affiliations

O M E Albagha, U Pettersson, A Stewart, F E A McGuigan, H M MacDonald, D M Reid, S H Ralston, The Bone Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK

Competing interests: none declared

REFERENCES


www.jmedgenet.com


